Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of Aerosolized Celecoxib Encapsulated Nanostructured Lipid Carrier in Non-small Cell Lung Cancer in Combination with Docetaxel

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

ABSTRACT

Purpose

Evaluation of in-vivo anticancer activity of aerosolized Celecoxib encapsulated Nanolipidcarriers (Cxb-NLC) as a single therapeutic agent and combined with intravenously administered Docetaxel (Doc) against non-small cell lung cancer.

Methods

Cxb-NLC were prepared by high-pressure homogenization and were characterized for its physicochemical characteristics. Metastatic A549 tumor model in Nu/Nu mice was used to evaluate response of aerosolized Cxb-NLC & Doc. Isolated lung tumor samples were analyzed for: a) DNA fragmentation and cleaved caspase-3 by immunohistochemistry, b) apoptotic and angiogenic protein markers by western blot, c) global proteomic alterations by an isobaric labeling quantitative proteomic method and d) toxicity studies of NLC.

Results

The particle size of Cxb-NLC was 217 ± 20 nm, while entrapment efficiency was more than 90%. Cxb-NLC and Doc alone and in combination showed 25 ± 4%, 37 ± 5%, and 67 ± 4% reduction in tumor size respectively compared to control. Proteomic analysis with combination treatment further revealed significantly decreased expression of multiple pro-survival and pro-metastasis proteins as well as tumor invasion markers and the expression of S100 family proteins, such as S100A6 and S100P were decreased by 2.5 and 1.6 fold.

Conclusions

Combination therapy with Cxb-NLC and Doc showed significant reduction in tumor growth which was further confirmed by proteomic analysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig 3
Fig. 4

Similar content being viewed by others

REFERENCES

  1. Whitehead CM, Earle KA, Fetter J, Xu S, Hartman T, Chan DC, et al. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther. 2003;2(5):479–88.

    CAS  PubMed  Google Scholar 

  2. Sharma S, White D, Imondi AR, Placke ME, Vail DM, Kris MG. Development of inhalational agents for oncologic use. J Clin Oncol. 2001;19(6):1839–47.

    CAS  PubMed  Google Scholar 

  3. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):588–99.

    Article  CAS  PubMed  Google Scholar 

  4. Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res. 2000;6(5):2006–11.

    CAS  PubMed  Google Scholar 

  5. Shaik MS, Chatterjee A, Jackson T, Singh M. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer. 2006;118(2):396–404.

    Article  CAS  PubMed  Google Scholar 

  6. Hida T, Kozaki K, Ito H, Miyaishi O, Tatematsu Y, Suzuki T, et al. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res. 2002;8(7):2443–7.

    CAS  PubMed  Google Scholar 

  7. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther. 2004;3(1):59–70.

    CAS  PubMed  Google Scholar 

  8. Sweeney CJ, Mehrotra S, Sadaria MR, Kumar S, Shortle NH, Roman Y, et al. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther. 2005;4(6):1004–12.

    Article  CAS  PubMed  Google Scholar 

  9. Fulzele SV, Chatterjee A, Shaik MS, Jackson T, Singh M. Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model. Pharm Res. 2006;23(9):2094–106.

    Article  CAS  PubMed  Google Scholar 

  10. Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PN, Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release. 2010;144(2):233–41.

    Article  CAS  PubMed  Google Scholar 

  11. Walker Jr JE, Odden AR, Jeyaseelan S, Zhang P, Bagby GJ, Nelson S, et al. Ethanol exposure impairs LPS-induced pulmonary LIX expression: alveolar epithelial cell dysfunction as a consequence of acute intoxication. Alcohol Clin Exp Res. 2009;33(2):357–65.

    Article  CAS  PubMed  Google Scholar 

  12. Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1–2):170–84.

    Article  CAS  PubMed  Google Scholar 

  13. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2–3):165–96.

    Article  CAS  PubMed  Google Scholar 

  14. Muller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242(1–2):121–8.

    Article  CAS  PubMed  Google Scholar 

  15. Ichite N, Chougule MB, Jackson T, Fulzele SV, Safe S, Singh M. Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin Cancer Res. 2009;15(2):543–52.

    Article  CAS  PubMed  Google Scholar 

  16. Menendez JA, del Mar Barbacid M, Montero S, Sevilla E, Escrich E, Solanas M, et al. Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. Eur J Cancer. 2001;37(3):402–13.

    Article  CAS  PubMed  Google Scholar 

  17. Ichite N, Chougule M, Patel AR, Jackson T, Safe S, Singh M. Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancer. Mol Cancer Ther. 2010;9(11):3003–14.

    Article  CAS  PubMed  Google Scholar 

  18. Bonvillain RW, Danchuk S, Sullivan DE, Betancourt AM, Semon JA, Eagle ME, et al. A nonhuman primate model of lung regeneration: detergent-mediated decellularization and initial in vitro recellularization with mesenchymal stem cells. Tissue Eng Part A. 2012;18(23–24):2437–52.

    Google Scholar 

  19. Zhou C, Zhong Q, Rhodes LV, Townley I, Bratton MR, Zhang Q, et al. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res. 2012;14(2):R45.

    Article  CAS  PubMed  Google Scholar 

  20. Gavina M, Luciani A, Villella VR, Esposito S, Ferrari E, Bressani I, et al. Nebulized hyaluronan ameliorates lung inflammation in cystic fibrosis mice. Pediatr Pulmonol. 2012. doi:10.1002/ppul.22637.

  21. Tseng CL, Wu SY, Wang WH, Peng CL, Lin FH, Lin CC, et al. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials. 2008;29(20):3014–22.

    Article  CAS  PubMed  Google Scholar 

  22. Guo Y, Singleton PA, Rowshan A, Gucek M, Cole RN, Graham DR, et al. Quantitative proteomics analysis of human endothelial cell membrane rafts: evidence of MARCKS and MRP regulation in the sphingosine 1-phosphate-induced barrier enhancement. Mol Cell Proteomics. 2007;6(4):689–96.

    Article  CAS  PubMed  Google Scholar 

  23. Pierce A, Unwin RD, Evans CA, Griffiths S, Carney L, Zhang L, et al. Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases. Mol Cell Proteomics. 2008;7(5):853–63.

    Article  CAS  PubMed  Google Scholar 

  24. Tan HT, Tan S, Lin Q, Lim TK, Hew CL, Chung MC. Quantitative and temporal proteome analysis of butyrate-treated colorectal cancer cells. Mol Cell Proteomics. 2008;7(6):1174–85.

    Article  CAS  PubMed  Google Scholar 

  25. Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci. 1986;75(5):433–8.

    Article  CAS  PubMed  Google Scholar 

  26. De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R, et al. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer. Lung Cancer. 2009;63(3):410–7.

    Article  PubMed  Google Scholar 

  27. Bulk E, Hascher A, Liersch R, Mesters RM, Diederichs S, Sargin B, et al. Adjuvant therapy with small hairpin RNA interference prevents non-small cell lung cancer metastasis development in mice. Cancer Res. 2008;68(6):1896–904.

    Article  CAS  PubMed  Google Scholar 

  28. Rehbein G, Simm A, Hofmann HS, Silber RE, Bartling B. Molecular regulation of S100P in human lung adenocarcinomas. Int J Mol Med. 2008;22(1):69–77.

    CAS  PubMed  Google Scholar 

  29. Brychtova V, Vojtesek B, Hrstka R. Anterior gradient 2: a novel player in tumor cell biology. Cancer Lett. 2011;304(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  30. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071–80.

    Article  CAS  PubMed  Google Scholar 

  31. Verschraegen CF, Gilbert BE, Loyer E, Huaringa A, Walsh G, Newman RA, et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res. 2004;10(7):2319–26.

    Article  CAS  PubMed  Google Scholar 

  32. Latimer P, Menchaca M, Snyder RM, Yu W, Gilbert BE, Sanders BG, et al. Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases. Exp Biol Med (Maywood). 2009;234(10):1244–52.

    Article  CAS  Google Scholar 

  33. Okamoto H, Shiraki K, Yasuda R, Danjo K, Watanabe Y. Chitosan-interferon-beta gene complex powder for inhalation treatment of lung metastasis in mice. J Control Release. 2011;150(2):187–95.

    Article  CAS  PubMed  Google Scholar 

  34. Zhang C, Hu W, Fang Y. 10-Hydroxycamptothecin aerosol treatment inhibits lung metastases in B16F10 melanoma mice models. Zhongguo Zhong Yao Za Zhi. 2011;36(5):618–23.

    CAS  PubMed  Google Scholar 

  35. Garbuzenko OB, Saad M, Betigeri S, Zhang M, Vetcher AA, Soldatenkov VA, et al. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm Res. 2009;26(2):382–94.

    Article  CAS  PubMed  Google Scholar 

  36. Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia. 2001;3(1):53–61.

    Article  CAS  PubMed  Google Scholar 

  37. Eibl G, Bruemmer D, Okada Y, Duffy JP, Law RE, Reber HA, et al. PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun. 2003;306(4):887–97.

    Article  CAS  PubMed  Google Scholar 

  38. Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res. 2003;9(4):1566–72.

    CAS  PubMed  Google Scholar 

  39. Diederichs S, Bulk E, Steffen B, Ji P, Tickenbrock L, Lang K, et al. S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res. 2004;64(16):5564–9.

    Article  CAS  PubMed  Google Scholar 

  40. Kimura K, Endo Y, Yonemura Y, Heizmann CW, Schafer BW, Watanabe Y, et al. Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. Int J Oncol. 2000;16(6):1125–31.

    CAS  PubMed  Google Scholar 

  41. Grum-Schwensen B, Klingelhofer J, Grigorian M, Almholt K, Nielsen BS, Lukanidin E, et al. Lung metastasis fails in MMTV-PyMT oncomice lacking S100A4 due to a T-cell deficiency in primary tumors. Cancer Res. 2010;70(3):936–47.

    Article  CAS  PubMed  Google Scholar 

  42. Tian T, Hao J, Xu A, Luo C, Liu C, Huang L, et al. Determination of metastasis-associated proteins in non-small cell lung cancer by comparative proteomic analysis. Cancer Sci. 2007;98(8):1265–74.

    Article  CAS  PubMed  Google Scholar 

  43. Bartling B, Rehbein G, Schmitt WD, Hofmann HS, Silber RE, Simm A. S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy. Eur J Cancer. 2007;43(13):1935–43.

    Article  CAS  PubMed  Google Scholar 

  44. Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC, et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell. 2005;7(3):263–73.

    Article  CAS  PubMed  Google Scholar 

  45. Zhou Z, Kozlowski J, Schuster DP. Physiologic, biochemical, and imaging characterization of acute lung injury in mice. Am J Respir Crit Care Med. 2005;172(3):344–51.

    Article  PubMed  Google Scholar 

  46. Hoy A, Leininger-Muller B, Kutter D, Siest G, Visvikis S. Growing significance of myeloperoxidase in non-infectious diseases. Clin Chem Lab Med. 2002;40(1):2–8.

    Article  CAS  PubMed  Google Scholar 

Download references

ACKNOWLEDGMENTS AND DISCLOSURES

Author acknowledges the financial support provided by NIH RCMI grant 5G12RR026260-03.

Author information

Authors and Affiliations

  1. College of Pharmacy and Pharmaceutical Sciences, Florida A&M University,, Tallahassee, Florida, 32307, USA

    Apurva R. Patel, Ram Patlolla & Mandip Singh

  2. Department of Pharmaceutical Sciences, College of Pharmacy, University of Hawaii at Hilo, Hilo, Hawaii, 96720, USA

    Mahavir B. Chougule

  3. Department of Chemistry,, Xavier University of Louisiana, New Orleans, Los Angeles, 70125, USA

    Townley I. & Guangdi Wang

Authors
  1. Apurva R. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mahavir B. Chougule
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Townley I.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ram Patlolla
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guangdi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mandip Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Mahavir B. Chougule or Mandip Singh.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplemental Table 1

(XLSX 76 kb)

Supplemental Table 2

(XLSX 51 kb)

Supplemental Table 3

(XLSX 40 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patel, A.R., Chougule, M.B., I., T. et al. Efficacy of Aerosolized Celecoxib Encapsulated Nanostructured Lipid Carrier in Non-small Cell Lung Cancer in Combination with Docetaxel. Pharm Res 30, 1435–1446 (2013). https://doi.org/10.1007/s11095-013-0984-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-013-0984-9

KEY WORDS

Search

Navigation